Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development
Sabrina Paganoni1,2, James D Berry1, Melanie Quintana3
1Sean M. Healey & AMG Center for ALS and Neurological Clinical Research Institute, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract:
Current therapeutic development in amyotrophic lateral sclerosis (ALS) relies on individual randomized clinical trials to test a specific investigational product in a single patient population. This approach has intrinsic limitations, including cost, time, and lack of flexibility. Adaptive platform trials represent a novel approach to investigate several interventions for a single disease in a continuous manner. Already in use in oncology, this approach is now being employed more often in neurology. Here, we describe a newly launched platform trial for ALS. The Healey ALS Platform Trial is testing multiple investigational products concurrently in people with ALS, with the goal of rapidly identifying novel treatments, biomarkers, and trial endpoints. ANN NEUROL 2022;91:165-175.
Insights
The Healey ALS Platform Trial accelerates amyotrophic lateral sclerosis (ALS) treatment discovery by testing multiple investigational drugs simultaneously. This adaptive approach aims to rapidly identify effective therapies and biomarkers for ALS patients.
Area of Science:
- Neurology
- Clinical Trials
- Drug Development
Background:
- Traditional amyotrophic lateral sclerosis (ALS) drug development uses costly, time-consuming single-product clinical trials.
- Existing methods for testing ALS therapeutics lack flexibility and efficiency.
- Adaptive platform trials offer a novel, continuous approach to investigate multiple interventions for a single disease.
Purpose of the Study:
- To introduce the Healey ALS Platform Trial, a novel adaptive trial for amyotrophic lateral sclerosis.
- To describe the methodology for concurrently testing multiple investigational products in ALS patients.
- To highlight the trial's goal of accelerating the identification of effective ALS treatments, biomarkers, and endpoints.
Main Methods:
- The Healey ALS Platform Trial employs an adaptive platform design.
- Multiple investigational products are tested concurrently in individuals with ALS.
- This approach allows for continuous enrollment and evaluation of treatments.
Main Results:
- The trial is designed to rapidly identify promising therapeutic candidates for ALS.
- Biomarker discovery and validation are integrated into the platform.
- Novel trial endpoints are being explored to improve efficiency.
Conclusions:
- Adaptive platform trials represent a significant advancement in ALS therapeutic development.
- The Healey ALS Platform Trial offers a more efficient and flexible model for drug discovery in ALS.
- This innovative approach has the potential to expedite the delivery of new treatments to patients with amyotrophic lateral sclerosis.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:22Alzheimer's Disease: Treatment